PLUR

Pluri (PLUR)

About Pluri (PLUR)

Pluri, Inc. is a clinical stage company, which engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory, and hematologic conditions. The firm focuses on the research, development, and manufacturing of cell-based products and technologies. Its products include Clinical Pipeline, PLX-Immune, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel.

Details

Daily high
$2.10
Daily low
$2.00
Price at open
$2.10
52 Week High
$5.96
52 Week Low
$2.00
Market cap
21.8M
Dividend yield
0.00%
Volume
14,512
Avg. volume
14,216
P/E ratio
-.70

Pluri News

Details

Daily high
$2.10
Daily low
$2.00
Price at open
$2.10
52 Week High
$5.96
52 Week Low
$2.00
Market cap
21.8M
Dividend yield
0.00%
Volume
14,512
Avg. volume
14,216
P/E ratio
-.70